Clopidogrel

Abstract

Clopidogrel was significantly more effective than aspirin in the prevention of vascular events (ischaemic stroke, myocardial infarction or vascular death) [corrected] in patients with atherothrombotic disease manifested by recent myocardial infarction, recent ischaemic stroke or symptomatic peripheral arterial occlusive disease [corrected] in the CAPRIE study. The overall tolerability profile of the drug was similar to that of aspirin, although gastrointestinal haemorrhage occurred significantly less often in clopidogrel recipients. The drug is widely used in combination with aspirin for the prevention of atherothrombosis after placement of intravascular stents, and available data suggest that this combination is as effective as ticlopidine plus aspirin for this indication.

Asymmetric Synthesis of Protected Arylglycines by Rhodium-Catalyzed Addition of Arylboronic Acids to N-tert-Butanesulfinyl Imino Esters

“…3 The synthesis of arylglycines is therefore an important goal in organic chemistry. 4 The addition of arylboronic acids to imino acids via the Petasis reaction is a powerful method for arylglycine synthesis 5 because it capitalizes on the commercial availability of a large number of diverse arylboronic acids displaying a wide array of functionality.…”

Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men

“…Clopidogrel, an ADP P2Y12 receptor antagonist, strongly inhibits formation of thrombosis by impeding platelet binding regardless of the degree of degranulation or blood flow status 2,3. Aspirin has antiplatelet effects by irreversible inhibition of the formation of thromboxane A2 by acetylation of platelet cyclooxygenase, thereby contributing to decreasing the mortality caused by myocardial infarction, stroke, and cardiovascular diseases 4.…”

Capillary Zone Electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies

“…It inhibits platelet aggregation by selective preventing of the binding adenosine diphosphate (ADP) to its platelet receptor and blocks the subsequent platelet aggregation. The drug is indicated for the reduction of thrombotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis [1]. It has an absolute S configuration at carbon 7, while the corresponding R enantiomer is devoid of anti-aggregating activity [2].…”